4568 N Stock Overview
Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 3/6 |
Past Performance | 5/6 |
Financial Health | 6/6 |
Dividends | 3/6 |
Daiichi Sankyo Company, Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | JP¥490.80 |
52 Week High | JP¥549.45 |
52 Week Low | JP¥461.08 |
Beta | 0.29 |
1 Month Change | n/a |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -16.72% |
Recent News & Updates
Recent updates
Shareholder Returns
4568 N | MX Pharmaceuticals | MX Market | |
---|---|---|---|
7D | 0% | 4.1% | -1.5% |
1Y | n/a | -14.0% | 1.8% |
Return vs Industry: Insufficient data to determine how 4568 N performed against the MX Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 4568 N performed against the MX Market.
Price Volatility
4568 N volatility | |
---|---|
4568 N Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 6.1% |
Market Average Movement | 4.1% |
10% most volatile stocks in MX Market | 6.1% |
10% least volatile stocks in MX Market | 2.0% |
Stable Share Price: 4568 N has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 4568 N's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1899 | 17,435 | Sunao Manabe | www.daiichisankyo.com |
Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol.
Daiichi Sankyo Company, Limited Fundamentals Summary
4568 N fundamental statistics | |
---|---|
Market cap | Mex$1.17t |
Earnings (TTM) | Mex$22.27b |
Revenue (TTM) | Mex$177.68b |
52.6x
P/E Ratio6.6x
P/S RatioIs 4568 N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
4568 N income statement (TTM) | |
---|---|
Revenue | JP¥1.60t |
Cost of Revenue | JP¥415.32b |
Gross Profit | JP¥1.19t |
Other Expenses | JP¥985.64b |
Earnings | JP¥200.73b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 104.68 |
Gross Margin | 74.07% |
Net Profit Margin | 12.53% |
Debt/Equity Ratio | 6.0% |
How did 4568 N perform over the long term?
See historical performance and comparison